Literature DB >> 15950450

Interactions between malaria parasites and the host immune system.

Christian R Engwerda1, Michael F Good.   

Abstract

Malaria remains one of the greatest impediments to development in many tropical regions of the world. Understanding host immune responses to malaria parasites is crucial for the effective design and implementation of new vaccines and drugs. Recent research has seen the identification of the first pattern recognition receptor (TLR9) on dendritic cells for a defined product of malaria infection (hemozoin). In addition, progress has been made in understanding the role of dendritic cell subsets in malaria, and how they promote specific components of the host immune response. Potentially important advances in vaccine design have also been made by inserting a Plasmodium sporozoite epitope into the yellow fever vaccine 17D, as well as using a whole, live-attenuated sporozoite vaccine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950450     DOI: 10.1016/j.coi.2005.05.010

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  16 in total

Review 1.  Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design.

Authors:  Javier E Garcia; Alvaro Puentes; Manuel E Patarroyo
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

2.  Competition for red blood cells can enhance Plasmodium vivax parasitemia in mixed-species malaria infections.

Authors:  Philip G McQueen; F Ellis McKenzie
Journal:  Am J Trop Med Hyg       Date:  2006-07       Impact factor: 2.345

3.  Dependence on p38 MAPK signalling in the up-regulation of TLR2, TLR4 and TLR9 gene expression in Trichomonas vaginalis-treated HeLa cells.

Authors:  Jae-Ho Chang; Ju-Youn Park; Soo-Ki Kim
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

4.  Population dynamics of a pathogen: the conundrum of vivax malaria.

Authors:  Philip G McQueen
Journal:  Biophys Rev       Date:  2010-08-10

5.  Dendritic cells and the malaria pre-erythrocytic stage.

Authors:  Marjorie Mauduit; Peter See; Kaitian Peng; Laurent Rénia; Florent Ginhoux
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

6.  Plasmepsin 4-deficient Plasmodium berghei are virulence attenuated and induce protective immunity against experimental malaria.

Authors:  Roberta Spaccapelo; Chris J Janse; Sara Caterbi; Blandine Franke-Fayard; J Alfredo Bonilla; Luke M Syphard; Manlio Di Cristina; Tania Dottorini; Andrea Savarino; Antonio Cassone; Francesco Bistoni; Andrew P Waters; John B Dame; Andrea Crisanti
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

7.  Effect of Brugia pahangi co-infection with Plasmodium berghei ANKA in gerbils (Meriones unguiculatus).

Authors:  Olawale Quazim Junaid; Indra Vythilingam; Loke Tim Khaw; Sinnadurai Sivanandam; Rohela Mahmud
Journal:  Parasitol Res       Date:  2020-03-16       Impact factor: 2.289

Review 8.  Hemozoin: oil versus water.

Authors:  John M Pisciotta; David Sullivan
Journal:  Parasitol Int       Date:  2007-10-13       Impact factor: 2.230

9.  Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria.

Authors:  Susanne Tartz; Jana Kamanova; Marcela Simsova; Peter Sebo; Stefanie Bolte; Volker Heussler; Bernhard Fleischer; Thomas Jacobs
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

10.  Inverse association of falciparum positivity with endemic Burkitt lymphoma is robust in analyses adjusting for pre-enrollment malaria in the EMBLEM case-control study.

Authors:  Sally Peprah; Martin D Ogwang; Patrick Kerchan; Steven J Reynolds; Constance N Tenge; Pamela A Were; Robert T Kuremu; Walter N Wekesa; Nestory Masalu; Esther Kawira; Isaac Otim; Ismail D Legason; Leona W Ayers; Kishor Bhatia; James J Goedert; Ruth M Pfeiffer; Sam M Mbulaiteye
Journal:  Infect Agent Cancer       Date:  2021-06-07       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.